Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT
Status: Recruiting
Location: See location...
Intervention Type: Procedure, Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:
• Patients with histologically proven high grade glioma
• Intention to start therapy
Locations
United States
California
UCLA / Jonsson Comprehensive Cancer Center
RECRUITING
Los Angeles
Contact Information
Primary
Soosan Roodbari
sroodbari@mednet.ucla.edu
310 794-1596
Time Frame
Start Date: 2015-08-25
Estimated Completion Date: 2026-08-25
Participants
Target number of participants: 50
Treatments
Experimental: Treatment (FDG PET/CT)
Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
Authors
Related Therapeutic Areas
Sponsors
Leads: Jonsson Comprehensive Cancer Center
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI)